INTRODUCTION {#s1}
============

One of the neuropathological hallmarks of Alzheimer\'s Disease (AD) is the neurofibrillary tangle, which contains paired helical filaments (PHFs) composed of hyperphosphorylated forms of the microtubule-associated protein tau (MAPT) by mechanism which is not illustrated \[[@R1]\]. Increasing attention has been paid to endogenous and exogenous factors, as well as genetic risk factors contributing to the incidence of AD \[[@R2]\], stimulating the disease progression of AD \[[@R3]\]. It was believed that the identification of key genetic determinants for AD might help further understand its underlying mechanism.

Human *MAPT* gene is located on chromosome 17q21. There have been conflicting results showing positive or negative findings on the association between the *MAPT* SNPs and AD risk. Some studies were showed that SNPs rs242557 \[[@R4], [@R5]\], rs3785883 \[[@R6]\] in US series, rs2471738 \[[@R6], [@R7]\] and rs1467967 \[[@R8]\] of the *MAPT* gene might been associated with increased AD risk. Some studies were, however, reported that rs242557 \[[@R8]--[@R10]\], rs3785883 \[[@R11]--[@R14]\], rs2471738 \[[@R11], [@R14], [@R15]\] and rs1467967 \[[@R7], [@R16]\] might not be associated with AD risk \[[@R10], [@R11], [@R13], [@R16], [@R17]\].

There are many factors leading to these different results about the association between the *MAPT* SNPs and AD risk. One of primary reasons is low statistical power and the limited sample size in each study. Therefore, we performed a meta-analysis on the association between the *MAPT* SNPs and AD risk by pooling all available published data. In this study, we evaluated the genetic heterogeneity of the studies included and then carried out a meta-analysis on the association between the *MAPT* SNPs (rs242557, rs2471738, rs3785883 and rs1467967) with AD risk to make a more accurate assessment of the relationship for greater power in detecting the disease associations.

RESULTS {#s2}
=======

Characteristic of eligible studies {#s2_1}
----------------------------------

The literature search was done on studies up to January 2017 and availability of an English-language abstract or paper for review; this yielded 208 hits (PubMed: 14, Google scholar: 194). 194 of these were excluded, including 16 duplicates, 67 non-AD case reports, 34 reviews, 34 irrelevant studies, 25 data not available, 10 abstracts, 5 non-English language papers (also non-Chinese) and 3 case reports. In total, 64 independent studies from 14 articles published from 2005 to 2016 providing data of the *MAPT* genotype, were included in the current meta-analysis (16 for rs242557, 14 for rs2471738, 14 for rs3785883 and 15 for rs1467967; Figure [1](#F1){ref-type="fig"}). We found that in all the studies included SNPs neither rs75721 (within exon 14) nor rs9468 (within exon 13) was significantly associated with increased AD risk (results not shown). So, we analyzed the associations between these SNPs (rs242557, rs2471738, rs3785883 and rs1467967) of the *MAPT* gene and AD risk involved in 14666/17532, 13812/17201, 14607/17883 and 15064/17687 cases/controls, respectively. The NOS results indicated that the methodological quality of these selected studies was generally good. The study characteristics were listed in Table [1](#T1){ref-type="table"}.

![Flow diagram of study selection](oncotarget-08-43506-g001){#F1}

###### Main characteristics of the studies included in this meta-analysis of the associations between these SNPs of the *MAPT* gene and AD risk

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SNP loci     Allele                      Ref no.      First author   Year    Country   Case (n)   CTR (n)   Case genotype   Control genotype   HWE~ct~   NOS                                  
  ------------ --------------------------- ------------ -------------- ------- --------- ---------- --------- --------------- ------------------ --------- ------ ------------ -------- ------- ---
  rs242557\    G \> A                      11           Abraham, R.    2009    UK        979        1139      144             456                379       143    563          433      0.054   8
  Exon 1                                                                                                                                                                                        

  13           Allen, M.(Mayo Cohort)      2014         USA            1802    3133      260        838       704             500                1373      1260   **0.0001**   8                

  13           Allen, M.(ADGC Cohort)      2014         USA            6705    6702      865        3082      2758            849                3081      2772   0.88         8                

  13           Allen, M.(JS)               2014         USA            828     932       124        386       318             141                404       387    **0.04**     8                

  13           Allen, M.(RS)               2014         USA            460     2201      60         215       185             359                969       873    **0.001**    8                

  8            Feulner, T. M.              2010         Germany        491     479       68         246       177             81                 220       178    0.36         9                

  9            Huin, V.                    2016         France         35      19        5          16        14              3                  9         7      0.97         7                

  5            Laws, S. M.                 2007         Germany        434     279       64         205       165             28                 120       131    0.99         8                

  4            Liu, Q. Y.                  2013         China          796     796       146        394       256             134                356       306    0.08         8                

  10           Mateo, I.(a)                2008         Spain          300     360       30         127       143             36                 153       171    0.84         8                

  16           Mukherjee, O.               2007         USA            361     358       47         166       148             49                 167       142    0.99         6                

  6            Myers, A. J.(US)            2005         USA            181     131       26         85        70              12                 55        64     0.97         8                

  6            Myers, A. J.(UK)            2005         UK             179     121       32         87        60              15                 55        51     0.98         8                

  6            Myers, A. J. (US)           2007         USA            296     128       36         135       125             17                 60        51     0.92         8                

  6            Myers, A. J. (US/UK)        2007         UK             655     380       94         309       252             44                 171       165    0.98         8                

  12           Seto-Salvia, N.             2011         Spain          164     374       19         74        71              38                 163       173    0.97         8                

  Total                                                                        14666     17532                                                                                                  

  APOE(+)      4                           Liu, Q. Y.   2013           China   200       122        44        96              60                 18        52     52           0.403    8       

  6            Myers, A. J. (US/UK)        2005         USA            360     252       55         171       134             34                 105       113    0.229        8                

  11           Abraham, R.                 2009         UK             597     271       83         271       243             21                 139       111    **0.012**    8                

  APOE(−)      4                           Liu, Q. Y.   2013           China   596       674        102       298             196                116       304    254          0.1291   8       

  6            Myers, A. J. (US/UK)        2005         USA            360     252       64         175       121             26                 109       117    0.9342       8                

  Total                                                                        2113      1571                                                                                                   

  rs2471738\   C \> T                      11           Abraham, R.    2009    UK        970        1125      50              333                587       61     388          676      0.59    8
  Intron 9                                                                                                                                                                                      

  13           Allen, M.(Mayo Cohort)      2014         USA            1980    3302      106        671       1203            135                1112      2055   0.31         8                

  13           Allen, M.(ADGC Cohort)      2014         USA            6942    7239      292        2265      4385            287                2315      4637   0.93         8                

  13           Allen, M.(JS)               2014         USA            851     947       39         297       515             28                 334       585    **0.02**     8                

  13           Allen, M.(RS)               2014         USA            585     2355      33         194       358             107                778       1470   0.75         8                

  14           Chang, C. W.                2014         China          109     108       6          38        65              7                  40        61     0.9          7                

  16           Mukherjee, O.               2007         USA            361     358       13         111       237             16                 119       223    0.98         6                

  15           Mateo, I.(b)                2008         Spain          293     396       8          84        201             9                  110       277    0.62         8                

  6            Myers, A. J.(US)            2005         USA            181     131       12         70        99              4                  39        88     0.9          8                

  6            Myers, A. J.(UK)            2005         UK             179     121       10         65        104             4                  36        81     1            8                

  6            Myers, A. J. (US)           2007         USA            296     128       14         102       180             2                  31        95     0.77         8                

  6            Myers, A. J. (US/UK)        2007         UK             655     380       38         239       378             10                 102       268    0.94         8                

  12           Seto-Salvia, N.             2011         Spain          164     374       3          41        120             12                 109       253    0.95         8                

  19           Vazquez-Higuera, J. L.      2009         Spain          246     237       9          64        173             5                  62        170    0.81         8                

  Total                                                                                  13812      17201                                                                                       

  rs3785883\   G \> A                      11           Abraham, R.    2009    UK        967        1139      29              272                666       33     332          774      0.72    8
  Intron 3                                                                                                                                                                                      

  13           Allen, M.(Mayo Cohort)      2014         USA            1954    3293      66         581       1307            110                982       2201   0.97         8                

  13           Allen, M.(ADGC Cohort)      2014         USA            7397    7790      254        2135      5008            235                2203      5352   0.65         8                

  13           Allen, M.(JS)               2014         USA            841     943       30         238       573             26                 267       650    0.82         8                

  13           Allen, M.(RS)               2014         USA            578     2350      23         176       379             84                 715       1551   0.89         8                

  14           Chang, C. W.                2014         China          108     108       3          31        74              2                  26        80     0.95         7                

  8            Feulner, T. M.              2010         Germany        491     479       28         148       315             21                 133       325    0.12         9                

  5            Laws, S. M.                 2007         Germany        433     279       11         118       304             11                 88        180    0.97         8                

  16           Mukherjee, O.               2007         USA            361     358       14         116       231             14                 115       229    0.93         6                

  6            Myers, A. J.(US)            2005         USA            181     131       5          51        125             6                  45        80     0.92         8                

  6            Myers, A. J.(UK)            2005         UK             181     131       3          41        137             3                  33        95     0.95         8                

  6            Myers, A. J. (US)           2007         USA            296     128       12         95        189             2                  27        99     0.92         8                

  6            Myers, A. J.(US/UK)         2007         UK             655     380       19         185       451             11                 107       262    0.98         8                

  12           Seto-Salvia, N.             2011         Spain          164     374       6          51        107             17                 124       233    0.92         8                

  Total                                                                                  14607      17883                                                                                       

  rs1467967\   A \> G                      11           Abraham, R.    2009    UK        982        1153      88              417                477       93     509          551      0.1     8
  Exon 1                                                                                                                                                                                        

  13           Allen, M.(Mayo Cohort)      2014         USA            1868    3118      220        812       836             340                1376      1402   0.93         8                

  13           Allen, M.(ADGC Cohort)      2014         USA            7110    7255      765        3151      3194            752                3232      3271   0.26         8                

  13           Allen, M.(JS)               2014         USA            831     905       91         372       368             85                 408       412    0.27         8                

  13           Allen, M.(RS)               2014         USA            536     2213      70         241       225             255                968       990    0.43         8                

  14           Chang, C. W.                2014         China          108     108       17         52        39              14                 50        44     0.97         7                

  21           Elias-Sonnenschein, L. S.   2013         Finnish        869     685       104        391       374             89                 308       288    0.64         8                

  8            Feulner, T. M.              2010         Germany        491     479       56         228       207             47                 191       241    0.31         9                

  5            Laws, S. M.                 2007         Germany        433     279       47         192       194             39                 131       109    0.97         8                

  6            Myers, A. J.(US)            2005         USA            181     131       18         79        84              19                 62        50     0.98         8                

  6            Myers, A. J.(UK)            2005         UK             179     121       18         78        83              13                 54        54     0.93         8                

  6            Myers, A. J. (US)           2007         USA            296     128       32         131       133             15                 57        56     0.93         8                

  6            Myers, A. J.(US/UK)         2007         UK             655     380       71         290       294             47                 173       160    0.98         8                

  16           Mukherjee, O.               2007         USA            361     358       42         162       157             46                 165       147    0.98         6                

  12           Seto-Salvia, N.             2011         Spain          164     374       14         67        83              26                 145       203    0.99         8                

  Total                                                                                  15064      17687                                                                                       
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: Ref no: reference number; NOS, the Newcastle-Ottawa Scale; CTR, control; HWEct, Hardy-Weinberg Equilibrium in controls;

Heterogeneity test {#s2_2}
------------------

The strength of the association was estimated in the allelic, dominant, recessive and additive models. The heterogeneity among studies was tested with Q statistic and further quantified by *I*^2^ statistic. As measured by the *I*^2^ (Table [2](#T2){ref-type="table"}), in this meta-analysis no significant heterogeneity existed between studies under all the genetic models tested for rs242557 (the range of *I*^2^ values from 0 to 33.1%), rs3785883 (the range of *I*^2^ values from 0 to 29.1%), and rs1467967 (the range of *I*^2^ values from 0 to 17.5%). Therefore, the fixed-effect model (Mantel-Haenszel method) was used to calculate the pooled ORs. However, for rs2471738 there was significant heterogeneity observed between studies under the allelic and dominant models (*I*^2^ = 62.0 and 57.1 for the allelic and dominant genetic models, respectively). Therefore, the random-effect model (Inverse Variance method) was used to calculate the pooled ORs under allelic and dominant models (fixed-effect model for the recessive and additive genetic models).

###### The genetic heterogeneity test

                                   Genetic model       *X*^2^      *p*         *I*^2^ (%)           
  -------------------------------- ------------------- ----------- ----------- ------------ ------- ------
  rs242557                         NO stratification   Allelic     A *vs*. G   22.42        0.097   33.1
  Dominant                         AA+AG *vs*. GG      18.94       0.216       20.8                 
  Recessive                        AA *vs*. AG+GG      18.50       0.237       18.9                 
  Additive                         AA *vs*. GG         21.35       0.126       29.8                 
  Stratified by *APOE* ε4 allele   Positive            Allelic     A *vs*. G   1.87         0.393   0
  negative                         Allelic             A *vs*. G   5.4         0.02         81.5    
  rs2471738                        Allelic             T *vs*. C   34.21       0.001        62.0    
  Dominant                         TT+TC *vs*. CC      30.32       0.004       57.1                 
  Recessive                        TT *vs*. TC+CC      14.68       0.328       11.5                 
  Additive                         TT *vs*. CC         18.39       0.143       29.3                 
  rs3785883                        Allelic             A *vs*. G   18.33       0.146        29.1    
  Dominant                         AA+AG *vs*. GG      16.29       0.234       20.2                 
  Recessive                        AA *vs*. AG+GG      6.17        0.94        0                    
  Additive                         AA *vs*. GG         7.97        0.846       0                    
  rs1467967                        Allelic             G *vs*. A   16.96       0.258        17.5    
  Dominant                         GG+AG *vs*. AA      15.12       0.37        7.4                  
  Recessive                        GG *vs*. AG+AA      8.7         0.85        0                    
  Additive                         GG *vs*. AA         13.19       0.512       0                    

Meta-analysis results of the association between SNP rs242557 and AD risk {#s2_3}
-------------------------------------------------------------------------

For rs242557 when the 16 studies were pooled into the meta-analysis using the fixed-effect model, a significant association was observed under the dominant (OR = 1.05, 95% CI = 1.01, 1.10, *P* = 0.025, Figure [3](#F3){ref-type="fig"}) model, and there was a trend under the allelic (OR = 1.03, 95% CI = 1.00, 1.06, *P =* 0.078, Figure [2](#F2){ref-type="fig"}) model. However, no significant association was found under the recessive (OR = 1.06, 95% CI = 0.95, 1.08, *P* = 0.766) and additive models (OR = 1.04, 95% CI = 0.97, 1.12, *P* = 0.223).

![Forest plot for the meta-analysis of the association of SNP rs242557 and AD risk under the allelic model (A *vs*. **G**)](oncotarget-08-43506-g002){#F2}

![Forest plot for the meta-analysis of the association of SNP rs242557 and AD risk under the dominant model (AA + AG *vs*. **GG**)](oncotarget-08-43506-g003){#F3}

When stratified by *APOE* ε4 carrier status, the association between the rs242557 SNP and AD risk was observed to be stronger in the individuals with *APOE* ε4-positive genotype (with no heterogeneity, *I*^2^ = 0, OR = 1.24, 95% CI = 1.08, 1.43, *P* = 0.003) than without stratification (OR = 1.03, 95% CI = 1.00, 1.06, *P =* 0.078) under the allelic model. But for the individuals with *APOE* ε4-negative genotype (*APOE* ε4-), there was large heterogeneity (*I*^2^ = 81.5, Table [2](#T2){ref-type="table"}) under the allelic model, and no significant association between the rs242557 SNP with AD risk (OR = 1.29, 95% CI = 0.93, 1.80, *P* = 0.132, Table [3](#T3){ref-type="table"}, Figure [4](#F4){ref-type="fig"}).

###### The pooled results of the associations between these SNPs and AD risk as well as publication bias evaluation of the studies included

  SNP locus   Genetic model   Effect model   *P*z        Pooled OR   95% CI          Publication bias (*p* value)                           
  ----------- --------------- -------------- ----------- ----------- --------------- ------------------------------ --------------- ------- -------
  rs242557    Allelic         A vs. G        Fixed       **0.078**   **1.03**        **1.00-1.06**                  0.753           0.982   
  Dominant    AA+AG vs. GG    Fixed          **0.025**   **1.05**    **1.01-1.10**   0.753                          0.933                   
  Recessive   AA vs. AG+GG    Fixed          0.766       1.06        0.95-1.08       0.558                          0.341                   
  Additive    AA vs. GG       Fixed          0.223       1.04        0.97-1.12       0.558                          0.337                   
              APOE (+)        Allelic        A vs. G     Fixed       **0.003**       **1.24**                       **1.08-1.43**   0.296   0.371
              APOE (−)        Allelic        A vs. G     Random      0.132           1.29                           0.93-1.80       1.0     \-
  rs2471738   Allelic         T vs. C        Random      **0.021**   **1.11**        **1.01-1.20**                  0.827           0.493   
  Dominant    TT+TC vs. CC    Random         **0.046**   **1.10**    **1.00-1.21**   0.101                          0.667                   
  Recessive   TT vs. TC+CC    Fixed          **0.004**   **1.18**    **1.05-1.32**   0.869                          0.589                   
  Additive    TT vs. CC       Fixed          **0.002**   **1.20**    **1.07-1.34**   0.189                          0.469                   
  rs3785883   Allelic         A vs. G        Fixed       0.179       1.03            0.99-1.07                      0.324           0.543   
  Dominant    AA+AG vs. GG    Fixed          0.32        1.02        0.98-1.07       0.189                          0.067                   
  Recessive   AA vs. AG+GG    Fixed          0.144       1.10        0.97-1.24       0.274                          0.732                   
  Additive    AA vs. GG       Fixed          0.126       1.10        0.97-1.25       0.101                          0.051                   
  rs1467967   Allelic         G vs. A        Fixed       0.447       1.01            0.98-1.05                      0.767           0.830   
  Dominant    GG+AG vs. AA    Fixed          0.737       1.01        0.96-1.05       0.921                          0.804                   
  Recessive   GG vs. AG+AA    Fixed          0.276       1.04        0.97-1.12       0.553                          0.572                   
  Additive    GG vs. AA       Fixed          0.301       1.04        0.97-1.12       0.692                          0.383                   

![Forest plot for the meta-analysis of the association of SNP rs242557 and AD risk stratified by *APOE* ε4 allele status](oncotarget-08-43506-g004){#F4}

Meta-analysis results of the association between SNP rs2471738 and AD risk {#s2_4}
--------------------------------------------------------------------------

A significant association between SNP rs2471738 and AD risk was identified under the allelic (random-effect, OR = 1.11, 95% CI = 1.01, 1.20, *P* = 0.021, Figure [5](#F5){ref-type="fig"} and Table [3](#T3){ref-type="table"}) and dominant (OR = 1.10, 95% CI = 1.00, 1.21, *P* = 0.046, Figure [6](#F6){ref-type="fig"} and Table [3](#T3){ref-type="table"}) models. A significant association between SNP rs2471738 and AD risk was also identified under the recessive (fixed-effect, OR = 1.18, 95% CI = 1.05, 1.32, *P* = 0.004, Figure [7](#F7){ref-type="fig"} and Table [3](#T3){ref-type="table"}) and additive (OR = 1.20, 95% CI = 1.07, 1.34, *P* = 0.002, Figure [8](#F8){ref-type="fig"} and Table [3](#T3){ref-type="table"}) models.

![Forest plot for the meta-analysis of the association of SNP rs2471738 and AD risk under the allelic model (T *vs*. **C**)](oncotarget-08-43506-g005){#F5}

![Forest plot for the meta-analysis of the association of SNP rs2471738 and AD risk under the dominant model (TT + TC *vs*. **CC**)](oncotarget-08-43506-g006){#F6}

![Forest plot for the meta-analysis of the association of SNP rs2471738 and AD risk under the recessive model (TT *vs*. **CC + TC**)](oncotarget-08-43506-g007){#F7}

![Forest plot for the meta-analysis of the association of SNP rs2471738 and AD risk under the additive model (TT *vs*. **CC**)](oncotarget-08-43506-g008){#F8}

Meta-analysis results of the associations between SNPs rs3785883 and rs1467967 and AD risk {#s2_5}
------------------------------------------------------------------------------------------

Using fixed-effect model, no significant association between SNP rs3785883 and AD risk was observed under all the four models (allelic: OR = 1.03, 95% CI = 0.99, 1.07, *P =* 0.179, Figure [9](#F9){ref-type="fig"}; dominant: OR = 1.02, 95% CI = 0.98, 1.07, *P =* 0.32; recessive: OR = 1.10, 95% CI = 0.97, 1.24, *P =* 0.144; additive: OR = 1.10, 95% CI = 0.97, 1.25, *P =* 0.126, Table [3](#T3){ref-type="table"}).

![Forest plot for the meta-analysis of the association of SNP rs3785883 and AD risk under the allelic model (A *vs*. **G**)](oncotarget-08-43506-g009){#F9}

Similarly, no significant association between SNP rs1467967 and AD risk was found under all the four models (fixed-effect, allelic: OR = 1.01, 95% CI = 0.98, 1.05, *P =* 0.449, Figure [10](#F10){ref-type="fig"}; dominant: OR = 1.01, 95% CI = 0.96, 1.05, *P =* 0.737; recessive: OR = 1.04, 95% CI = 0.97, 1.12, *P =* 0.276; additive: OR = 1.04, 95% CI = 0.97, 1.12, *P =* 0.301, Table [3](#T3){ref-type="table"}).

![Forest plot for the meta-analysis of the association of SNP rs1467967 and AD risk under the allelic model (G *vs*. **A**)](oncotarget-08-43506-g010){#F10}

Sensitivity analysis and evaluation of publication bias {#s2_6}
-------------------------------------------------------

Due to large heterogeneity between studies for rs2471738, we performed a sensitivity analysis by excluding a study \[Allen, M. (JS), 2014; see Table [1](#T1){ref-type="table"}\] with departure from Hardy-Weinberg Equilibrium (HWE) in controls, we did not observe increased homogeneity across the rest studies (data not shown), suggesting that HWE deviation was not a source of between-study heterogeneity. The sensitivity analysis showed that for rs242557 and rs2471738 none of the studies included significantly changed the results under the allelic model (Figure [11A](#F11){ref-type="fig"} and [11B](#F11){ref-type="fig"}, respectively). The same results were observed for rs3785883/rs1467967 (Figure [12](#F12){ref-type="fig"} A and 12B, respectively). Begg\'s and Egger\'s test were used to estimate the severity of publication bias with a *P-value* \< 0.05 being considered statistically significant. No evidence of publication bias was found in any genetic model (Table [3](#T3){ref-type="table"}).

![Sensitivity analysis for rs242557 A. and rs2471738 B. under the allelic model](oncotarget-08-43506-g011){#F11}

![Sensitivity analysis for rs3785883 A. and rs1467967 B. under the allelic model](oncotarget-08-43506-g012){#F12}

DISCUSSION {#s3}
==========

Tau protein is specifically expressed in neurons, directly interacts with tubulin and mediates its assembly \[[@R18]\]. It was found that the *MAPT* rs242557 (within exon 1) SNP was significantly associated with late-onset AD in 1592 Han Chinese subjects \[[@R4]\], in the German population \[[@R5]\] and in the US series \[[@R7]\]. However, it was reported that this SNP was not significantly associated with AD risk \[[@R10], [@R11]\] in the UK series \[[@R7]\]. For the rs2471738 (within intron 9) SNP, study findings revealed that there was significant association in the US series \[[@R6], [@R7]\] and US/UK series \[[@R6]\], or no \[[@R19]\] in 293 AD patients and 396 healthy controls \[[@R15]\], in 361 AD patients and 358 controls \[[@R16]\]. For the rs3785883 (within intron 3) SNP, it was found that there was significant association \[[@R13]\], or no \[[@R5], [@R14], [@R20]\]. For the rs1467967 (within exon 1) SNP, it was showed that there was significant association \[[@R5]\], or no \[[@R7], [@R11], [@R21]\]. There were consistent results on the association between the rs7521 \[[@R6], [@R7], [@R11], [@R22]\] and rs9468 \[[@R11]\] (too little data) SNPs and AD risk. Thus, these four SNPs of the *MAPT* gene were a matter of controversy.

Therefore, we conducted this meta-analysis to explore the association between the *MAPT* SNPs and AD risk. In summary, results from this meta-analysis suggest that of these SNPs tested, rs242557 is significantly associated with increased AD risk under the dominant genetic model, and the rs2471738 SNP is significantly associated with increased AD risk under all the four genetic model. In the stratified analysis by *APOE* ε4 allele status, *APOE* ε4 allele carriers, but not *APOE* ε4 allele non-carriers, were showed to be significantly associated with increased AD risk. This result indicates that there appears to be a gene-gene interaction between the *APOE* and the *MAPT* genes, which could increase susceptibility to AD. More studies should, however, be conducted to assess the interaction.

Because of the moderate heterogeneity, we conducted sensitivity analyses to evaluate the effects of each study on the combined ORs by sequential removal of each eligible study. The sensitivity analysis showed that none of these studies changed the significance of the combined ORs under the allelic model. It was showed that Allele A of rs242557 with the H1p promoter variant had 2.7-fold greater transcriptional activity than allele G with the H1p promoter variant and 4.2-fold greater than allele G with the H2p promoter variant. The H1 haplotype increases the expression of total *MAPT* transcript \[[@R6]\]; allele A (AA + AG) of rs242557 was associated with CSF total tau levels elevated levels compared to non-carriers (GG) \[[@R5]\], indicating that SNP rs242557 might be associated with the increased expression levels of tau protein. Trabzuni, D. et al \[[@R23]\]. found that the H1c haplotype (tagged by rs242557) was not significantly associated with increased mRNA expression of the *MAPT*, suggesting that there are other things about possible consequence of this SNP on the *MAPT*, which is needed for further investigations. In the current meta-analysis, SNP rs3785883 was found not to be associated with AD risk under all the genetic models; in AD cases, however, there was higher levels of Total tau mRNA in those individuals who carry rs3785883 minor allele (AA or AG) than those with non-carriers (GG) with evidence of beta-amyloid deposition \[[@R24]\], suggesting that SNP rs3785883, which changes the expression of the marker protein of AD, but is not associated with AD risk, might be an complicated SNP of the MAPT gene.

There are some limitations to this meta-analysis. First, the total number of studies was not large enough for such analyses to give meaningful interpretation, and only published studies were included in the meta-analysis. To be made, however, this approach requires the authors of all of the studies to share their data. Second, there was evidence of moderate heterogeneity between studies, in particularly for rs2471738. Third, the present meta-analysis failed to consider the possibility of gene-gene or SNP-SNP interactions in which further investigations are needed. So it is quite important to have more studies and sample in the future so that more precise conclusion about the association between the SNPs of the *MAPT* gene and AD risk could be achieved.

In conclusion, our meta-analysis confirmed the following: SNPs rs242557 and rs2471738 might be associated with increased AD risk, but rs3785883 and rs1467967 not. More well-conducted studies with larger sample size are needed to confirm our conclusion.

MATERIALS AND METHODS {#s4}
=====================

Search strategies {#s4_1}
-----------------

All of the potential eligible studies were screened based on the electronic databases (PubMed and Google Scholar) up to 1st Jun. 2017. Systematic searching was performed using the combination of "Alzheimer\*", "rs242557 OR rs3785883 OR rs2471738 OR rs1467967 OR rs75721 OR rs9468".

Inclusion and exclusion criteria {#s4_2}
--------------------------------

Only studies published as full-length articles in peer-reviewed journals were considered in the analysis. The eligible studies must satisfy the following inclusion criteria: i) concerning the association between the *MAPT* gene (including SNPs rs242557, rs3785883, rs2471738, rs1467967, rs75721 and rs9468) and AD risk; ii) case-control study design; iii) sufficient information accessible (e.g. sample size for each study, allele or genotype frequencies of these SNPs); iv) cases meeting the clinical criteria for AD. The exclusion criteria include: a duplicated publication; a review; a case report; not reported the genotype frequencies; non-AD cases, a review; an irrelevant study; datum not available; an abstract; in neither English nor Chinese; inconsistent with most studies in major allele size.

Data extraction {#s4_3}
---------------

Data extracted from the included studies were as follows: first author, year of publication, country, sample size of cases and controls, numbers of case and control genotypes, *p-value* for HWE in controls and Newcastle-Ottawa Scale (NOS) Quality Assessment Scale. The inclusion/exclusion criteria were applied by 2 (ZFT and WDL) independent reviewers. We used the NOS to assess the quality of the included studies. A quality score was calculated based on three major components. Each component of the criteria scored 1 if present or 0 if absent. The scores were summed and a higher score represents better methodological quality.

Meta-analysis {#s4_4}
-------------

All statistical analyses were performed using Stata software (College Station, TX). The association between the *MAPT* SNPs and AD risk was evaluated by pooled ORs and corresponding 95% CIs. Four genetic models, including allelic (G *vs*. A), dominant (AA + AG *vs*. GG), recessive (AA *vs*. AG + GG) and additive (AA *vs*. GG), were used to estimate this association. Sensitivity analyses were performed to determine whether undue influence of a single study was present. The possibility of publication bias was assessed by Begg\'s and Egger\'s test (*P* \< 0.05 was considered as representative of statistically significant publication bias).
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